Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M21,939Revenue $M16,697Net Margin (%)14.2Altman Z-Score2.7
Enterprise Value $M29,270EPS $4.3Operating Margin %15.9Piotroski F-Score5
P/E(ttm)9.3Beneish M-Score-2.7Pre-tax Margin (%)14.2Higher ROA y-yN
Price/Book3.010-y EBITDA Growth Rate %10.9Quick Ratio1.0Cash flow > EarningsY
Price/Sales1.35-y EBITDA Growth Rate %5.5Current Ratio1.6Lower Leverage y-yY
Price/Free Cash Flow29.2y-y EBITDA Growth Rate %-2.3ROA % (ttm)9.3Higher Current Ratio y-yN
Dividend Yield %5.2PEG2.1ROE % (ttm)28.8Less Shares Outstanding y-yY
Payout Ratio %61.0Shares Outstanding M544ROIC % (ttm)14.2Gross Margin Increase y-yN

Gurus Latest Trades with BAX

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
BAXVanguard Health Care Fund 2015-06-30 Buy 0.15%$34.81 - $39.3
($37.38)
$ 40.298%New holding1,945,220
BAXKen Fisher 2015-06-30 Buy $34.81 - $39.3
($37.38)
$ 40.298%New holding3,652
BAXRichard Pzena 2015-03-31 Add0.41%$36.39 - $39.82
($37.91)
$ 40.296%Add 27.49%5,028,418
BAXJoel Greenblatt 2015-03-31 Add0.13%$36.39 - $39.82
($37.91)
$ 40.296%Add 4622.98%244,934
BAXFirst Eagle Investment 2015-03-31 Reduce-0.12%$36.39 - $39.82
($37.91)
$ 40.296%Reduce 99.84%1,100
BAXDavid Dreman 2015-03-31 Add0.03%$36.39 - $39.82
($37.91)
$ 40.296%Add 124.77%7,876
BAXTweedy Browne 2015-03-31 Reduce-0.01%$36.39 - $39.82
($37.91)
$ 40.296%Reduce 0.29%2,564,814
BAXCharles Brandes 2015-03-31 Reduce-0.01%$36.39 - $39.82
($37.91)
$ 40.296%Reduce 3.40%229,981
BAXJohn Keeley 2015-03-31 Add0.01%$36.39 - $39.82
($37.91)
$ 40.296%Add 26.95%53,460
BAXMario Gabelli 2015-03-31 Reduce$36.39 - $39.82
($37.91)
$ 40.296%Reduce 4.66%164,850
BAXRichard Pzena 2014-12-31 Buy 1.5%$36.52 - $40.58
($38.95)
$ 40.293%New holding3,944,140
BAXBill Nygren 2014-12-31 Sold Out -0.75%$36.52 - $40.58
($38.97)
$ 40.293%Sold Out0
BAXFirst Eagle Investment 2014-12-31 Reduce-0.06%$36.52 - $40.58
($38.95)
$ 40.293%Reduce 32.14%676,637
BAXMario Gabelli 2014-12-31 Reduce-0.02%$36.52 - $40.58
($38.95)
$ 40.293%Reduce 23.14%172,900
BAXJoel Greenblatt 2014-12-31 Buy $36.52 - $40.58
($38.97)
$ 40.293%New holding5,186
BAXRobert Olstein 2014-09-30 Sold Out -0.59%$38.72 - $41.83
($40.64)
$ 40.29-1%Sold Out0
BAXDavid Dreman 2014-09-30 Buy 0.02%$38.72 - $41.83
($40.64)
$ 40.29-1%New holding3,397
BAXFirst Eagle Investment 2014-06-30 Add0.18%$39.1 - $40.98
($40.02)
$ 40.291%Add 90872.40%1,000,696
BAXVanguard Health Care Fund 2014-06-30 Sold Out -0.11%$39.1 - $40.98
($40.02)
$ 40.291%Sold Out0
BAXJohn Keeley 2014-06-30 Buy 0.05%$39.1 - $40.98
($40.02)
$ 40.291%New holding37,150
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

BAX is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


BAX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Shapazian Carole JDirector 2015-05-22Sell1,533$67.68-40view
STROUCKEN ALBERT P LDirector 2015-04-27Sell4,830$71.06-42.85view
STORM KORNELIS J.Director 2015-04-27Sell4,830$71.05-42.84view
GAVIN JAMES R IIIDirector 2015-04-27Sell4,830$71.06-42.85view
HELLMAN PETER SDirector 2015-02-06Sell4,830$71.32-43.06view
FORSYTH JOHN DDirector 2014-08-15Sell4,830$74.9-45.78view
Shapazian Carole JDirector 2014-07-25Sell1,645$76.98-47.25view
STALLKAMP THOMAS TDirector 2014-07-24Sell8,300$76.82-47.14view
HANTSON LUDWIGCorporate Vice President 2014-07-09Sell24,693$76-46.57view
STROUCKEN ALBERT P LDirector 2014-05-27Sell3,840$74.41-45.42view

Quarterly/Annual Reports about BAX:

News about BAX:

Articles On GuruFocus.com
Baxalta: A Rare Undervalued Biopharmaceutical Company Jul 23 2015 
John Rogers' Undervalued Stocks Trading With Low P/E Ratio Jul 14 2015 
Baxter Takes The Acquisition Route To Grow In The Oncology Segment May 14 2015 
Live Off Your Monthly Dividend Portfolio Mar 19 2015 
Medtronic Inc. (MDT) Dividend Stock Analysis Feb 25 2015 
To Reinvest or Not Reinvest: That is the Question Feb 19 2015 
Best Stock Pick For Long Term Investors Feb 10 2015 
Richard Pzena's New Buys Feb 09 2015 
Richard Pzena's 5 New Q4 Stock Buys Feb 06 2015 
Expectations, Price, and Fundamentals (Or Congressional Questions Gone Awry) Jan 23 2015 

More From Other Websites
Shire Mounts Bid Worth $30 Billion For U.S. Biotech Aug 04 2015
Shire Offers $30 Billion For Ex-Baxter Unit Baxalta Aug 04 2015
Drugmaker Shire bids $30 billion for Baxter spin-off Baxalta Aug 04 2015
Drugmaker Shire bids $30 bln for Baxter spin-off Baxalta Aug 04 2015
Drugmaker Shire bids $30 bln for Baxter spin-off Baxalta Aug 04 2015
Baxter International (BAX) Earnings Report: Q2 2015 Conference Call Transcript Jul 30 2015
Baxter Beats on Q2 Earnings & Sales, 2H15 View Tepid - Analyst Blog Jul 30 2015
Baxter downgraded by Leerink Partners Jul 30 2015
Edited Transcript of BAX earnings conference call or presentation 29-Jul-15 9:00pm GMT Jul 29 2015
Baxter International Inc Earnings Call scheduled for 5:00 pm ET today Jul 29 2015
Baxter Reports Strong Second Quarter Financial Results Exceeding Guidance Jul 29 2015
Baxter Declares Quarterly Dividend Jul 29 2015
Baxter posts 2Q profit Jul 29 2015
Baxter posts 2Q profit Jul 29 2015
Will Baxter Int'l. (BAX) Stock be Affected by Strong Second Quarter Earnings Results? Jul 29 2015
BAXTER INTERNATIONAL INC Files SEC form 8-K, Results of Operations and Financial Condition,... Jul 29 2015
Baxter Declares Quarterly Dividend Jul 29 2015
Baxter Reports Strong Second Quarter Financial Results Exceeding Guidance Jul 29 2015
Thermo Fisher Scientific, Inc. Earnings Analysis: By the Numbers Jul 29 2015

Add Notes, Comments

If you want to ask a question, or report a bug, please create a support ticket.

User Comments

Sww
ReplySww - 1 year ago
Bax medical devices revenue ~9b, bio science ~7b
using 3X sales of medical devices company and 4X for drugs company, 27b+28b = 55b market cap,as of June 2014, BAX market cap is 39b, so it can sell for

72 * (1 + 16/39) = 99

72 is current stock price, with an upside of around 35%

so my guess is BAX may be able to sell for around 90 after spin-off.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK